Activation of Transcription Factor MEF2D by Bis(3)-cognitin Protects Dopaminergic Neurons and Ameliorates Parkinsonian Motor Defects*

Background: Dysregulation of myocyte enhancer factor 2D (MEF2D) is implicated in the pathogenic process of Parkinson disease (PD). Results: A small molecule bis(3)-cognitin activates MEF2D and protects Parkinsonian impairments. Conclusion: Bis(3)-cognitin provides protection of dopaminergic neurons in a model of PD by reversing MEF2D dysfunction. Significance: Activation of MEF2D by pharmacological approach has the potential to be a novel therapeutic for PD. Parkinson disease (PD) is characterized by the selective demise of dopaminergic (DA) neurons in the substantial nigra pars compacta. Dysregulation of transcriptional factor myocyte enhancer factor 2D (MEF2D) has been implicated in the pathogenic process in in vivo and in vitro models of PD. Here, we identified a small molecule bis(3)-cognitin (B3C) as a potent activator of MEF2D. We showed that B3C attenuated the toxic effects of neurotoxin 1-methyl-4-phenylpyridinium (MPP+) by activating MEF2D via multiple mechanisms. B3C significantly reduced MPP+-induced oxidative stress and potentiated Akt to down-regulate the activity of MEF2 inhibitor glycogen synthase kinase 3β (GSK3β) in a DA neuronal cell line SN4741. Furthermore, B3C effectively rescued MEF2D from MPP+-induced decline in both nucleic and mitochondrial compartments. B3C offered SN4741 cells potent protection against MPP+-induced apoptosis via MEF2D. Interestingly, B3C also protected SN4741 cells from wild type or mutant A53T α-synuclein-induced cytotoxicity. Using the in vivo PD model of C57BL/6 mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP), we showed that B3C maintained redox homeostasis, promoted Akt function activity, and restored MEF2D level in midbrain neurons. Moreover, B3C greatly prevented the loss of tyrosine hydroxylase signal in substantial nigra pars compacta DA neurons and ameliorated behavioral impairments in mice treated with MPTP. Collectedly, our studies identified B3C as a potent neuroprotective agent whose effectiveness relies on its ability to effectively up-regulate MEF2D in DA neurons against toxic stress in models of PD in vitro and in vivo.

[1]  W. Severt,et al.  Disease Modification in Parkinson’s Disease , 2011, Drugs & aging.

[2]  W. Poewe,et al.  Milestones in Parkinson's disease therapeutics , 2011, Movement disorders : official journal of the Movement Disorder Society.

[3]  G. Scapagnini,et al.  Modulation of Nrf2/ARE Pathway by Food Polyphenols: A Nutritional Neuroprotective Strategy for Cognitive and Neurodegenerative Disorders , 2011, Molecular Neurobiology.

[4]  Y. Smith,et al.  Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. , 2011, The Journal of clinical investigation.

[5]  J. Kordower,et al.  α-synuclein aggregation reduces nigral myocyte enhancer Factor-2D in idiopathic and experimental Parkinson's disease , 2011, Neurobiology of Disease.

[6]  Hai-Jie Yang,et al.  Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+-induced apoptosis by AKT/GSK-3β/JNK signaling , 2010, Apoptosis.

[7]  G. Miller,et al.  Behavioral phenotyping of mouse models of Parkinson's disease , 2010, Behavioural Brain Research.

[8]  Min Zhang,et al.  Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta. , 2010, Toxicology.

[9]  Dik‐Lung Ma,et al.  Pathologically Activated Neuroprotection via Uncompetitive Blockade of N-Methyl-d-aspartate Receptors with Fast Off-rate by Novel Multifunctional Dimer Bis(propyl)-cognitin* , 2010, The Journal of Biological Chemistry.

[10]  David S. Park,et al.  DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway , 2010, Proceedings of the National Academy of Sciences.

[11]  Z. Mao,et al.  Phosphorylation of Neuronal Survival Factor MEF2D by Glycogen Synthase Kinase 3β in Neuronal Apoptosis* , 2009, The Journal of Biological Chemistry.

[12]  C. Warren Olanow,et al.  Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions , 2009, Neurobiology of Disease.

[13]  M. Gearing,et al.  Regulation of Neuronal Survival Factor MEF2D by Chaperone-Mediated Autophagy , 2009, Science.

[14]  S. Mandel,et al.  Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases , 2008, CNS neuroscience & therapeutics.

[15]  M. Beal,et al.  Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis , 2008, Nature Clinical Practice Neurology.

[16]  M. Beal,et al.  PPAR: a therapeutic target in Parkinson’s disease , 2008, Journal of neurochemistry.

[17]  Yizheng Wang,et al.  Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity , 2007, Neuropharmacology.

[18]  Angelika Richter,et al.  Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice , 2007, Journal of neuroscience research.

[19]  S. Przedborski,et al.  Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.

[20]  M. Beal,et al.  Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases , 2006, Nature.

[21]  Erwan Bezard,et al.  Novel pharmacological targets for the treatment of Parkinson's disease , 2006, Nature Reviews Drug Discovery.

[22]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[23]  David S. Park,et al.  Calpain-Regulated p35/cdk5 Plays a Central Role in Dopaminergic Neuron Death through Modulation of the Transcription Factor Myocyte Enhancer Factor 2 , 2006, The Journal of Neuroscience.

[24]  M. Beal,et al.  Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. Li,et al.  PI3K/Akt‐dependent regulation of the transcription factor myocyte enhancer factor‐2 in insulin‐like growth factor‐1‐ and membrane depolarization‐mediated survival of cerebellar granule neurons , 2005, Journal of neuroscience research.

[26]  David S. Park,et al.  Cyclin-Dependent Kinase 5 Mediates Neurotoxin-Induced Degradation of the Transcription Factor Myocyte Enhancer Factor 2 , 2005, The Journal of Neuroscience.

[27]  Ming-tao Li,et al.  Novel Dimeric Acetylcholinesterase Inhibitor Bis(7)-tacrine, but Not Donepezil, Prevents Glutamate-induced Neuronal Apoptosis by Blocking N-Methyl-d-aspartate Receptors* , 2005, Journal of Biological Chemistry.

[28]  Z. Mao,et al.  Regulation of Neuroprotective Activity of Myocyte-enhancer Factor 2 by cAMP-Protein Kinase A Signaling Pathway in Neuronal Survival* , 2005, Journal of Biological Chemistry.

[29]  S. Friedman,et al.  Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. , 2004, Gastroenterology.

[30]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[31]  Z. Xia,et al.  ERK5 activation of MEF2-mediated gene expression plays a critical role in BDNF-promoted survival of developing but not mature cortical neurons , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Cuadrado,et al.  Nerve Growth Factor Protects against 6-Hydroxydopamine-induced Oxidative Stress by Increasing Expression of Heme Oxygenase-1 in a Phosphatidylinositol 3-Kinase-dependent Manner* , 2003, The Journal of Biological Chemistry.

[33]  Junmin Peng,et al.  Cdk5-Mediated Inhibition of the Protective Effects of Transcription Factor MEF2 in Neurotoxicity-Induced Apoptosis , 2003, Neuron.

[34]  Todd B. Sherer,et al.  An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.

[35]  Jiankun Cui,et al.  Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. K. Meintzer,et al.  Myocyte Enhancer Factor 2A and 2D Undergo Phosphorylation and Caspase-Mediated Degradation during Apoptosis of Rat Cerebellar Granule Neurons , 2001, The Journal of Neuroscience.

[37]  Hui Zhang,et al.  Dopaminergic cell death induced by MPP+, oxidant and specific neurotoxicants shares the common molecular mechanism , 2001, Journal of neurochemistry.

[38]  M E Greenberg,et al.  Neuronal activity-dependent cell survival mediated by transcription factor MEF2. , 1999, Science.

[39]  Z. Mao,et al.  Calcineurin Enhances MEF2 DNA Binding Activity in Calcium-dependent Survival of Cerebellar Granule Neurons* , 1999, The Journal of Biological Chemistry.

[40]  K. Prasad,et al.  Multiple antioxidants in the prevention and treatment of Parkinson's disease. , 1999, Journal of the American College of Nutrition.

[41]  T. Joh,et al.  Neuroprotection and Neuronal Differentiation Studies Using Substantia Nigra Dopaminergic Cells Derived from Transgenic Mouse Embryos , 1999, The Journal of Neuroscience.

[42]  E. López-Martín,et al.  The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism , 1998, Journal of Neuroscience Methods.

[43]  S. Kish,et al.  In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining , 1997, Neuroscience.

[44]  S. Brimijoin,et al.  Highly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase , 1996, The Journal of Biological Chemistry.

[45]  Samuel M. Goldman,et al.  EPIDEMIOLOGY OF PARKINSON'S DISEASE , 1996, Neurologic Clinics.

[46]  Jerry J Buccafusco,et al.  Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. , 2005, Trends in pharmacological sciences.

[47]  P. Jenner,et al.  Oxidative stress in Parkinson's disease , 2003, Annals of neurology.

[48]  J. Benito-León,et al.  [Epidemiology of Parkinson disease]. , 1998, Neurologia.

[49]  C. Olanow Oxidative Stress in Parkinson's Disease , 1997 .